TNFRSF17 and neoplasm: We observed strong myeloma progression localized to typical myeloma sites in bone marrow of miR-H18 SP6 CAR T cell-treated mice over 2 weeks, significantly less expansion in the BCMA CAR T cell cohort, and potent suppression of tumor growth in the miR-H18 BCMA CAR T cell group (Figures 6E and 6F).